Kevin P Starr's Net Worth

$1.34 Billion

Estimate Recalculated Feb 20, 2024 04:13PM EST

Who is Kevin P Starr?

Kevin P Starr has an estimated net worth of $1.34 Billion. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Fulcrum Therapeutics, Inc., Revolution Medicines, Inc., PLIANT THERAPEUTICS, INC., Editas Medicine, Inc., Voyager Therapeutics, Inc., Blueprint Medicines Corp, Nurix Therapeutics, Inc., Relay Therapeutics, Inc., Foundation Medicine, Inc., Decibel Therapeutics, Inc., Eleven Biotherapeutics, Inc., CytomX Therapeutics, Inc., Jounce Therapeutics, Inc., Global Blood Therapeutics, Inc., ALNYLAM PHARMACEUTICALS, INC., AGIOS PHARMACEUTICALS INC, CONSTELLATION PHARMACEUTICALS INC, Sage Therapeutics, Inc., MyoKardia Inc, Neon Therapeutics, Inc., ZAFGEN, INC., Allena Pharmaceuticals, Inc., and HUMAN GENOME SCIENCES INC.

SEC CIK

Kevin P Starr's CIK is 0001192603

Past Insider Trading and Trends

2015 was Kevin P Starr's most active year for acquiring shares with 43 total transactions. Kevin P Starr's most active month to acquire stocks was the month of May. 2015 was Kevin P Starr's most active year for disposing of shares, totalling 48 transactions. Kevin P Starr's most active month to dispose stocks was the month of October. 2018 saw Kevin P Starr paying a total of $4,079,104.60 for 12,374,669 shares, this is the most they've acquired in one year. In 2021 Kevin P Starr cashed out on 21,434,231 shares for a total of $322,683,542.21, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $47.7901

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-25.12%
-1.00M
2.98M
Scheduled
Aug 30
Form 4
+22,487.15%
3.96M
3.98M
Oct 10
Form 3
0
0
No matching records found

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Snapshot price: $168.83

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Jun 2
Form 4
0
0
Jun 3
Form 4
0
$58.02
-$6,880,868.26
0
Scheduled
Nov 11 - Nov 12
Form 4
0
0
Jun 1
Form 4
0
$47.47
-$5,512,288.56
0
Scheduled
Sep 24 - Sep 25
Form 4
0
0
Jun 5
Form 4
0
0
Jan 2
Form 4
0
0
Jun 6
Form 4
0
$12.22
-$1,186,134.20
0
Scheduled
Mar 25 - Mar 26
Form 4
0
0
Jun 21
Form 4
0
0
Jun 9
Form 4
0
0
Jun 2
Form 4
0
0
Jun 11
Form 4
0
0
Jun 3
Form 4
0
0
Jun 1
Form 4
0
0
Jun 1
Form 4
0
0
Jun 8
Form 3
0
0
No matching records found

AGIOS PHARMACEUTICALS INC (AGIO) Snapshot price: $24.15

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-94.05%
-2.91M
184.39K
Feb 19
Form 4
-20.86%
-816.23K
3.1M
Sep 11
Form 4
-29.68%
-1.65M
3.91M
Jun 24
Form 4
0
0
May 30
Form 4
+920.14%
5.02M
5.56M
Jul 29
Form 3
0
0
No matching records found

CONSTELLATION PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+1.71%
51.03K
$1.55
$79,099.60
3.03M
Aug 22
Form 4
+26,895.94%
2.97M
$15.00
2.98M
Jul 23
Form 3
0
0
No matching records found

Fulcrum Therapeutics, Inc. (FULC) Snapshot price: $8.01

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-20.15%
-1.00M
3.96M
Scheduled
Nov 10
Form 4
-16.77%
-1.00M
4.96M
Scheduled
Sep 22
Form 4
+1,986.77%
5.68M
$16.00
5.96M
Jul 22
Form 3
0
0
No matching records found